Phase 2 study of vismodegib, a hedgehog inhibitor, combined with gemcitabine and nab-paclitaxel in patients with untreated metastatic pancreatic adenocarcinoma

BACKGROUND: The Hedgehog (Hh) signalling pathway is overexpressed in pancreatic ductal adenocarcinoma (PDA). Preclinical studies have shown that Hh inhibitors reduce pancreatic cancer stem cells (pCSC), stroma and Hh signalling. METHODS: Patients with previously untreated metastatic PDA were treated...

Celý popis

Uloženo v:
Podrobná bibliografie
Vydáno v:Br J Cancer
Hlavní autoři: De Jesus-Acosta, Ana, Sugar, Elizabeth A., O’Dwyer, Peter J., Ramanathan, Ramesh K., Von Hoff, Daniel D., Rasheed, Zeshaan, Zheng, Lei, Begum, Asma, Anders, Robert, Maitra, Anirban, McAllister, Florencia, Rajeshkumar, N. V., Yabuuchi, Shinichi, de Wilde, Roeland F., Batukbhai, Bhavina, Sahin, Ismet, Laheru, Daniel A.
Médium: Artigo
Jazyk:Inglês
Vydáno: Nature Publishing Group UK 2019
Témata:
Article
On-line přístup:https://ncbi.nlm.nih.gov/pmc/articles/PMC7029016/
https://ncbi.nlm.nih.gov/pubmed/31857726
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1038/s41416-019-0683-3
Tagy: Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!

Podobné jednotky